DOCS (Doximity) 5-Year EBITDA Growth Rate: 28.20% (As of Mar. 2026)


DOCS Doximity Inc DOCS
82 GF Score
Price $21.69
GF Value $49.24
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Doximity 5-Year EBITDA Growth Rate?

Doximity DOCS -4.62% 82 5-Year EBITDA Growth Rate is 28.20% as of Mar. 2026. GuruFocus rates DOCS with a GF Score™ of 82/100 and a GF Value™ of $49.24 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Doximity's EBITDA per Share for the three months ended in Mar. 2026 was $0.15.

During the past 12 months, Doximity's average EBITDA Per Share Growth Rate was -3.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 22.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 28.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Doximity was 141.70% per year. The lowest was 22.00% per year. And the median was 40.40% per year.

Doximity  (NYSE:DOCS) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Doximity 5-Year EBITDA Growth Rate Related Terms

DOCS vs WAY, PRVA, HTFL: 5-Year EBITDA Growth Rate Comparison

For the Health Information Services subindustry, Doximity's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Doximity 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Doximity's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Doximity's 5-Year EBITDA Growth Rate falls into.


DOCS
82GF Score
Doximity Inc DOCS
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Doximity 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 28.20% mean?
Doximity (DOCS) has a 5-Year EBITDA Growth Rate of 28.20% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Doximity and its competitors.
Is Doximity's 5-Year EBITDA Growth Rate too high?
Doximity's current 5-Year EBITDA Growth Rate is 28.20%. Overall, Doximity has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's 5-Year EBITDA Growth Rate compare to WAY and PRVA?
Doximity's 5-Year EBITDA Growth Rate of 28.20% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Doximity and its competitors. Doximity's current 5-Year EBITDA Growth Rate is 28.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (DOCS) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.24, compared to a current price of $21.69 — trading 56% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 28.20%. Doximity's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Doximity (DOCS), the current 5-Year EBITDA Growth Rate is 28.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Doximity (DOCS) Overvalued in 2026?

Based on GuruFocus' analysis, Doximity stock appears to be undervalued. The current stock price of $21.69 is trading 56% below its estimated GF Value™ of $49.24. GuruFocus considers Doximity to be Significantly Undervalued.

Key valuation signals for DOCS:

  • 5-Year EBITDA Growth Rate: 28.20%
  • GF Value™: $49.24 vs. price of $21.69 (56% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the DOCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Doximity Business Description

Other Exchanges D2OC34:Brazil
Address 500 3rd Street, Suite 510, San Francisco, CA, USA, 94107
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
82GF Score

Get the complete analysis for DOCS

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.69
Price
$49.24
GF Value